Ki67在乳腺癌新辅助内分泌治疗中的意义  

The Significance of Ki67 Index in Neoadjuvant Endocrine Therapy of Breast Cancer

作　　者：张艾琳 毛晓韵[1] ZHANG Ai-ling;MAO Xiao-yun(Department of Breast Surgery,The First Affiliated Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院乳腺外科,沈阳110001

出　　处：《循证医学》2020年第5期311-315,共5页The Journal of Evidence-Based Medicine

基　　金：国家自然科学基金资助项目(81972791)。

摘　　要：近年来,随着乳腺癌新辅助治疗研究的持续升温,一系列重要的预测因子在新辅助疗效评估及预后中显示出重要的作用。Ki67作为细胞增殖相关核抗原,其表达高低与细胞周期中的有丝分裂相关,在肿瘤研究中扮演着重要的角色。Ki67也被作为乳腺癌分子分型及预后的重要指标。根据其临床实用价值,国外已将Ki67作为激素受体阳性乳腺癌新辅助内分泌治疗的重要评估指标,并将用Ki67取代肿瘤瘤灶变小的传统临床终点,最终用于评估新辅助内分泌治疗终点。本文就其在新辅助内分泌治疗中的意义及标准化评估方法进行综述。Many researches are carried out and focused on neoadjuvant therapy for breast cancer in recent years,many biomarkers are considered to be important predictors for the evaluation of neoadjuvant therapy efficacy.The proliferation marker Ki67,a component of the mitotic chromosome periphery,plays an important role in cancer research.Ki67 is essential for determining breast cancer molecular subtype and a perfect predictor of breast cancer prognosis.According to its clinical practical value,Ki67 is used to be an important evaluation index and predictors in hormone receptors positive breast cancer patients with neoadjuvant endocrine therapy.It turns out to be a primary efficacy endpoint in the clinical trial of neoadjuvant endocrine treatment,more important than other evaluation of target lesions.This review aims to elucidate the significance and the assessment guidelines of Ki67 index in neoadjuvant endocrine therapy of hormone receptors positive breast cancer.

关 键 词：乳腺癌 新辅助内分泌治疗 Ki67指数 

分 类 号：R737.9[医药卫生—肿瘤]